Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Diplopia
RCT	150 people, 150 eyes with pseudophakic rhegmatogenous retinal detachment (RRD)	Diplopia 3/75 (4%) with scleral buckling 0/75 (0%) with pars plana vitrectomy with infusion of short-acting gas	P = 0.25		Not significant
RCT	50 people, 50 eyes with pseudophakic RRD	Diplopia 1/25 (4%) with scleral buckling 0/25 (0%) with pars plana vitrectomy with infusion of long-acting gas	Significance not assessed
Proliferative vitreoretinopathy
RCT	50 people, 50 eyes with pseudophakic RRD	Proliferative vitreoretinopathy (PVR) 5/25 (20%) with scleral buckling 1/25 (4%) with pars plana vitrectomy with infusion of long-acting gas	Significance not assessed
RCT	265 people, 265 eyes with pseudophakic or aphakic RRD Subgroup analysis	PVR 30/133 (23%) with scleral buckling 20/132 (15%) with pars plana vitrectomy with infusion of short-acting gas	P = 0.1073 Results should be interpreted with caution (see further information on studies for full details)		Not significant
Macular pucker
RCT	150 people, 150 eyes with pseudophakic RRD	Macular pucker 3/75 (4%) with scleral buckling 2/75 (3%) with pars plana vitrectomy with infusion of short-acting gas	P = 0.99		Not significant
RCT	225 people, 225 eyes with pseudophakic or aphakic RRD	Macular pucker 22% with scleral buckling 22% with pars plana vitrectomy with infusion of short-acting gas Absolute numbers not reported	Significance not assessed
Retinal re-detachment
RCT	225 people, 225 eyes with pseudophakic or aphakic RRD	Retinal re-detachment 40/126 (32%) with scleral buckling 39/99 (37%) with pars plana vitrectomy with infusion of short-acting gas	Reported as not significant P value not reported		Not significant
RCT	265 people, 265 eyes with pseudophakic or aphakic RRD Subgroup analysis	Retinal re-detachment 1 year 53/133 (40%) with scleral buckling 27/132 (20%) with pars plana vitrectomy with infusion of short-acting gas	Significance not assessed Results should be interpreted with caution (see further information on studies for full details)
General adverse effects
RCT	150 people, 150 eyes with pseudophakic RRD	Postoperative retinal breaks 5/75 (7%) with scleral buckling 1/75 (1%) with pars plana vitrectomy with infusion of short-acting gas	Significance not assessed
RCT	150 people, 150 eyes with pseudophakic RRD	Choroidal haemorrhage or subretinal haemorrhage related to subretinal fluid drainage 8/75 (11%) with scleral buckling 0/75 (0%) with pars plana vitrectomy with infusion of short-acting gas	Significance not assessed
RCT	150 people, 150 eyes with pseudophakic RRD	Mean axial length 0.95 mm with scleral buckling 0.1 mm with pars plana vitrectomy with infusion of short-acting gas	P = 0.0001	Effect size not calculated	vitrectomy
RCT	50 people, 50 eyes with pseudophakic RRD	Raised intraocular pressure 1/25 (4%) with scleral buckling 8/25 (32%) with pars plana vitrectomy with infusion of long-acting gas	Significance not assessed
RCT	50 people, 50 eyes with pseudophakic RRD	Cellophane maculopathy 4/25 (16%) with scleral buckling 3/25 (12%) with pars plana vitrectomy with infusion of long-acting gas	Significance not assessed
RCT	50 people, 50 eyes with pseudophakic RRD	Myopic shift (mean change in refractive error) –1.38 dioptres of myopia with scleral buckling –0.85 dioptres of myopia with pars plana vitrectomy with infusion of long-acting gas	Significance not assessed
RCT	225 people, 225 eyes with pseudophakic or aphakic RRD	Macular oedema 6% with scleral buckling 10% with pars plana vitrectomy with infusion of short-acting gas Absolute numbers not reported	Significance not assessed
RCT	225 people, 225 eyes with pseudophakic or aphakic RRD	Extraocular muscle dysfunction 4% with scleral buckling 0% with pars plana vitrectomy with infusion of short-acting gas Absolute numbers not reported	Significance not assessed